| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3797660 | Medicina Clínica | 2016 | 6 Pages |
Abstract
In conclusion, afatinib should be considered as a treatment option in patients with EGFR mutations who show disease progression after a first tyrosine-kinase inhibitor.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Ángel Artal Cortés, JoaquÃn Gimeno PelegrÃn, MarÃa Álvarez Alejandro,